Dan Troy

Health and Human Services Secretary Robert F. Kennedy Jr.’s plans to rewrite the rules concerning pharmaceutical advertising is hardly novel. Every few years Washington revives this perennial idea—typically proffered to “save” money or “protect” patients from “misleading” messaging.  But as a former First Amendment lawyer who became chief counsel of the Food and Drug Administration and later the general counsel of a leading pharmaceutical company, I state…